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Skin flaps are extensively used in reconstructive surger-
ies to repair large defects and deep wounds, but severe 
ischemia and necrosis often results in loss of the trans-
planted tissue. Thus, skin flap models are often used to 
study the biology of healing and necrosis of acute isch-
emic wounds. Delivery of exogenous vascular endothe-
lial growth factor (VEGF) to areas of ischemia has shown 
promise for promoting therapeutic angiogenesis, but its 
expression must be tightly regulated to avoid adverse 
effects. In this study, plasmid DNA encoding VEGF165 
(pVEGF) was delivered to the ischemic skin of a rat skin 
flap model by intradermal injection followed by elec-
troporation (EP) (pVEGFE+). Treatment with pVEGFE+ 
significantly increased VEGF expression for 5 days after 
delivery compared to injection of pVEGF without EP 
(pVEGFE−). The short-term increase in VEGF was suf-
ficient to mediate an upregulation of endothelial nitric 
oxide synthase, an angiogenic factor that increases vas-
cular permeability. pVEGFE+ significantly increased skin 
flap perfusion at both days 10 and 14 postoperatively. 
The observed increase in perfusion with pVEGFE+ cor-
related with an increase in skin flap healing and survival. 
Our results demonstrate that pVEGFE+ is a potential 
nonviral noninvasive therapy to increase perfusion and 
healing of skin flaps and ischemic wounds.
Received 22 December 2008; accepted 12 January 2009; 
published online 24 February 2009. doi:10.1038/mt.2009.12
IntroductIon
Skin flaps are frequently used in plastic and reconstructive sur-
geries to repair large skin defects and deep wounds formed from 
injuries, surgeries, ulcerations, or congenital defects. In skin flap 
surgery, a piece of full thickness skin is transferred to the affected 
area while remaining attached to the donor site by a vascular 
pedicle. Skin flaps are grouped into two general categories, axial 
and random. Axial skin flaps are perfused by a single direct sub-
cutaneous artery through the vascular pedicle while random skin 
flaps (RSFs) are perfused by small musculocutaneous or septo-
cutaneous perforators.1 In both axial and RSFs, insufficient arte-
rial supply and inadequate venous drainage can lead to distal skin 
flap ischemia and necrosis.2 Despite the intense use of skin flaps 
as a model to study the healing and necrosis of ischemic wounds, 
a viable clinical solution to prevent distal necrosis and enhance 
healing remains elusive. Gene therapy techniques delivering exog-
enous angiogenic growth factors and cytokines, such as vascular 
endothelial growth factor (VEGF), to skin flaps are currently being 
investigated to increase skin flap perfusion and healing.3
In vascular endothelial cells, VEGF induces cell proliferation, 
promotes cell migration, differentiation, and inhibits apoptosis. 
VEGF expression is potentiated in response to hypoxia, by acti-
vated oncogenes, and by a variety of cytokines. The angiogenic and 
blood vessel permeability effects of VEGF are mediated by bind-
ing to the tyrosine kinase receptors VEGF Receptor 1 and VEGF 
Receptor 2. Signaling through VEGF Receptor 1 mediates VEGF-
induced migration of monocytes while signaling through VEGF 
Receptor 2 mediates the mitogenic and vessel permeability effects 
of VEGF.4 VEGF-mediated increases in vascular permeability are 
largely due to an increase in the downstream angiogenic growth 
factor endothelial nitric oxide synthase (eNOS) that mediates an 
increase in the release of the vasodilator nitric oxide.5,6 In vivo 
and in vitro studies demonstrated that the level of VEGF expres-
sion must be finely regulated to induce successful angiogenesis7–10 
and, more recently, that high levels of VEGF may inhibit new ves-
sel stabilization.11 High levels of constitutive VEGF expression 
can result in edema,12 formation of hemangiomas, and unstable 
immature vessels.7–11 In contrast, low levels or premature cessa-
tion of VEGF expression results in regression of the newly formed 
vessels.13 Thus, the development of a gene therapy approach that 
allows for tight control over expression level and duration would 
be advantageous for VEGF-mediated therapeutic angiogenesis.
Direct injection of naked plasmid DNA has been intensively 
investigated as a gene delivery approach for the treatment of a 
variety of diseases. One drawback to this approach is that ineffi-
cient uptake of the plasmid by the cells results in low levels of gene 
expression.14 In vivo electroporation (EP) has been successfully 
used to increase the uptake and expression of naked plasmid DNA 
in the skin and other target tissues. Electrically mediated delivery 
of plasmid DNA to the skin could potentially be used to deliver 
plasmids with therapeutic potential to treat a variety of diseases 
and has recently shown promise in a clinical trial.15 In previous 
work, we developed a novel electrode, the four-plate electrode, 
and optimized conditions using this electrode for cutaneous gene 
delivery with minimal tissue damage.16 Here, we show that using 
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the four-plate electrode to deliver pVEGFE+ to the ischemic skin 
of a modified McFarlane17,18 8 cm × 3 cm RSF increases VEGF 
expression more than pVEGFE−. Although the increase in VEGF 
expression was short-term, it was sufficient to induce an endog-
enous angiogenic response and increase perfusion and survival of 
the distal area of the RSF. These results suggest that pVEGFE+ 
is a potential novel therapeutic approach to increase healing and 
decrease necrosis of ischemic wounds and RSFs.
results
electrically mediated intradermal delivery of  
pVeGF increases VeGF expression and promotes  
a VeGF-mediated increase in enos expression
Plasmids encoding a wide variety of genes with therapeutic poten-
tial, including VEGF,19 have been successfully delivered to skeletal 
muscle by intramuscular injection with EP.20 Delivery of plasmids 
with EP significantly increased transgene expression compared 
to injection of the plasmid alone. Before delivering plasmid DNA 
encoding VEGF165 (pVEGF) to the RSF model, we first evaluated 
whether it could increase VEGF levels in vitro (data not shown) 
and in vivo by delivering pVEGFE+ and pVEGFE− to the rat gas-
trocnemius muscle. On days 2, 5, 7, and 10 after pVEGF delivery, 
muscle was excised from the delivery site and assayed for VEGF 
expression by enzyme-linked immunosorbent assay. Compared 
to pVEGFE−, pVEGFE+ significantly increased VEGF expression 
at both days 2 and 5 after delivery (Figure 1a) but VEGF levels 
returned to background levels by day 7 after delivery (data not 
shown). Because pVEGFE+ successfully increased VEGF expres-
sion in gastrocnemius muscle we then investigated whether the 
same increase could be achieved with pVEGFE+ in the skin of the 
RSF model.
Skin flaps were treated on day 2 postoperatively. On days 2, 5, 
8, and 12 after treatment, skin samples from the delivery sites were 
harvested and assayed for VEGF expression using an enzyme-
linked immunosorbent assay that specifically detects human 
VEGF165. Necrosis prevented all sites from being harvested, espe-
cially in the pVEGFE− group at later time points. At both 2 and 
5 days after delivery, VEGF expression was significantly higher in 
the pVEGFE+ treatment group compared to the pVEGFE− treat-
ment group (P < 0.05, both time points). VEGF expression was 
determined for each treatment group for delivery to the proximal 
area, closest to the RSF pedicle, and distal area, farthest from the 
RSF pedicle. Interestingly, 2 days after pVEGF delivery, VEGF 
expression was significantly higher in the distal area of the RSF, 
compared to the proximal area, for the pVEGFE+ treatment 
group (P < 0.05). In the pVEGFE− treatment group, there was a 
twofold increase in VEGF expression in the distal area, but this 
increase was not statistically significant (P = 0.157). The level of 
VEGF expression achieved with pVEGFE+ in the distal area of 
the RSF was similar to the level and duration observed in the 
gastrocnemius (Figure 1a,b). Compared to day 2 after delivery 
there was an overall significant decrease in VEGF expression at 
day 5 after delivery (P < 0.05, both treatment groups in both the 
proximal and distal areas) but levels were still significantly higher 
with pVEGFE+ (P < 0.05) (Figure 1b). At day 8 after delivery 
there was not a significant increase in VEGF expression with 
pVEGFE+ in either the proximal or distal area of the RSF, and by 
day 12 only background levels of VEGF were detected for both 
pVEGFE+ and pVEGFE−. VEGF expression was not detected 
when the vector backbone lacking the VEGF cDNA insert was 
delivered to the RSF with EP (pVAXE+), in the skin of untreated 
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Figure 1 VeGF expression kinetics. pVEGFE+ significantly increased 
VEGF compared to pVEGFE−. (a) pVEGFE+ increased VEGF expression 
in gastrocnemius muscle. Day 2: n = 6 per group. Day 5: pVEGFE− 
n = 5; pVEGFE+ n = 4. (b) Two and 5 days after delivery VEGF expres-
sion was significantly greater with pVEGFE+ than pVEGFE− in the RSF. 
VEGF expression was further increased in the distal region of the RSF. 
pVEGFE−: day 2 proximal n = 8, distal n = 6; day 5 proximal n = 3, distal 
n = 4; day 8 proximal n = 3, distal n = 2; and day 12 proximal and distal 
n = 2. pVEGFE+: day 2 proximal n = 4, distal n = 7; day 5 proximal n = 7, 
distal n = 6; day 8 proximal n = 3, distal n = 4; and day 12 both proxi-
mal and distal n = 3. (c) pVEGFE+ significantly increased eNOS expres-
sion in the distal area of the RSF 2 days after delivery; n = 7 per group 
per time point. For groups with n ≤ 3 the mean ± SD is reported. For 
groups with n > 3 the mean ± SEM is reported. *P < 0.05 compared to 
pVEGFE−. ‡P < 0.01 compared to pVAXE+. eNOS, endothelial nitric oxide 
synthase; pVEGFE+, mice injected with pVEGF followed by electropora-
tion; pVEGFE−, rats injected with pVEGF without electroporation; VEGF, 
vascular endothelial growth factor; pVAXE+, empty vector control.
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controls (P-E−), or in serum samples at any time point during the 
study (data not shown).
Both in vitro and in vivo studies6,21 have shown that increases 
in VEGF can increase levels of eNOS. To determine whether 
pVEGFE+ and pVEGFE− increased eNOS in the RSF, skin samples 
from the distal area of the RSF were assayed for eNOS by enzyme-
linked immunosorbent assay at days 2 and 5 after delivery. Two 
days after delivery eNOS was significantly higher with pVEGFE+ 
treatment compared to pVEGFE− treatment (P < 0.05), but by 
day 5 after delivery eNOS levels were similar in the pVEGFE+ 
and pVEGFE− treatment groups (Figure 1c). The application of 
an electric field to tissues alone can transiently induce expression 
of some genes22 but pVAXE+ did not increase eNOS in the RSF 
model (P < 0.01).
electrically mediated delivery of pVeGF increases 
perfusion to the distal area of the rsF
Therapeutic angiogenesis aims to increase perfusion to the affected 
area thereby decreasing the effects of ischemia and preventing 
necrosis. Because RSF survival shows little change after day 15 
postoperatively18 we monitored skin flap perfusion and healing 
for 14 days postoperatively. pVEGFE+ resulted in the highest level 
of VEGF expression in the distal area of RSFs which is more at 
risk for ischemia and necrosis because it is farthest from the vas-
cular pedicle. We next evaluated whether pVEGFE+ treatment 
increased perfusion more than control treatments in the distal 
area of the RSF, corresponding to ~25% of the total skin flap area. 
A Laser Doppler Imager was used to measure perfusion preop-
eratively (baseline), immediately postoperatively (day 0) and on 
days 2, 4, 7, 10, and 14 postoperatively. A sharp decrease in distal 
perfusion was observed immediately postoperatively through day 
4 postoperatively indicating that the RSF was effectively rendered 
ischemic. Perfusion for each treatment group is reported as the 
percent recovery of baseline (Figure 2a) and postoperative perfu-
sion (Figure 2b). At days 10 and 14 postoperatively, perfusion was 
significantly different between all treatment groups for both recov-
ery of baseline and postoperative perfusion (P < 0.01). Perfusion 
in the pVEGFE+ treatment group was significantly greater than 
all controls on both days 10 and 14 postoperatively for both recov-
ery of baseline (P < 0.01) and postoperative (P < 0.05) perfusion.
electrically mediated delivery of pVeGF promotes 
healing and decreases necrosis
Visual assessment of skin flap viability over the time course of the 
study showed a clear decrease in distal necrosis in the pVEGFE+ 
treatment group compared to control groups (Figure 3a). The 
surviving region of the distal area of the RSFs, corresponding to 
~25% of the total skin flap area, was quantitated on days 7 and 
14 postoperatively (Figure 3b). To quantitate the percent survival 
of the distal area, the area of skin with normal texture and color 
was expressed as a percent of the total distal area. Nonsurviving 
areas were defined as dark, rigid necrotic skin or scabbed necrotic 
lesions and surviving areas were defined as normal in texture and 
color. The pVEGFE+ treatment increased distal RSF survival at 
day 7 postoperatively (89.4 ± 4.3, P < 0.05) compared to pVEGFE− 
(56.6 ± 10.6), pVAXE+ (59.3 ± 9.8) and P-E− (60.2 ± 9.6). The sur-
viving area in all treatment groups increased ~5–10% at day 14 
postoperatively, but healing was still greater and more consistent in 
the pVEGFE+ group (95.2 ± 2.2) (P < 0.01) compared to pVEGFE− 
(65.6 ± 9.3), pVAXE+ (70.6 ± 7.4) and P-E− (73.5 ± 4.1). Adverse 
side effects associated with increased VEGF expression levels, 
such as edema,7–10 were not observed by gross visual assessment 
in any of the treatment groups. The mean percent survival of the 
pVEGFE− group at day 7 postoperatively in our study is similar to 
previously reported values delivering a plasmid encoding VEGF 
to a similar RSF model.23 On day 14 postoperatively, skin samples 
were excised 2-cm from the distal end of the RSFs for histological 
analysis by hematoxylin–eosin staining (Figure 3c). If the skin was 
necrotic at 2-cm from the distal end samples were excised near 
the edge of the surviving border. Skin from the pVEGFE+ treat-
ment group appeared healthy (Figure 3c, A,B) while skin from the 
pVEGFE− treatment group showed evidence of acute inflamma-
tion, necrosis, and myonecrosis (Figure 3c, C–F).
dIscussIon
In addition to direct injection of plasmid DNA, the most preva-
lent methods of therapeutic delivery of VEGF to skin flaps docu-
mented in the literature are adenoviral-mediated gene transfer 
and recombinant protein injection. These methods are also prom-
ising for increasing skin flap healing3,24,25 but have draw backs. 
In human clinical trials, adenoviral vectors have caused inflam-
matory responses, formation of antibodies to the adenoviruses, 
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Figure 2 pVeGFe+ increases perfusion. Perfusion was measured in the 
distal region of the RSF by Laser Doppler Imaging at the indicated time 
points. pVEGFE+ significantly increased recovery of (a) baseline and (b) 
postoperative perfusion on days 10 and 14 postoperatively  compared 
to all controls; n = 7 per group, per time point. *P < 0.05, **P < 0.01 
compared to all controls. pVEGFE+, rats injected with pVEGF followed by 
electroporation; RSF, random skin flaps.
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transient fever,26 and hepatotoxicity.27 Also, adenoviral delivery 
results in long-term and high levels of gene expression increas-
ing the potential for the occurrence of the adverse side effects 
associated with continuous unregulated VEGF expression.7–10 
Recombinant VEGF protein injection has also shown beneficial 
effects on skin flap viability, but its use in a clinical setting is not 
practical due to its short half-life, poor bioavailability, and con-
sequently the need for frequent administration to sustain lasting 
effects.28,29 Moreover, intravenous injection of recombinant VEGF 
was more effective than local administration25 for decreasing 
skin flap necrosis, which again raises the concern of pathological 
angiogenesis that may result from systemic VEGF expression.7–10
Here, we have presented a novel therapeutic approach to 
increase VEGF expression, induce an endogenous angiogenic 
response, increase perfusion, and decrease necrosis of the distal 
area of RSFs. The skin is an attractive target for delivery of plas-
mid DNA because it allows for enhanced control over expression 
levels and aids in targeting expression to specific tissue areas. 
Further, if higher expression levels are needed, the area treated 
or number of treatments can be increased. Previous gene ther-
apy studies delivered VEGF to skin flaps either preoperatively or 
intraoperatively.3,24,25 Our study was the first to deliver pVEGF 2 
days postoperatively. VEGF modulates the proliferative phase of 
wound healing that begins 2–4 days after the wound is created, and 
is characterized by angiogenesis, collagen deposition, granulation 
tissue formation, epithelialization, and wound contraction.30 By 
administering pVEGFE+ 2 days postoperatively, we timed VEGF 
expression to peak during the beginning of the proliferative phase 
of wound healing. Also, by administering treatment 2 days post-
operatively, when the distal area of the skin flap is most hypoxic,31 
we also determined that electrically mediated plasmid delivery to 
a large area of ischemic skin is in fact possible. Our results dem-
onstrate that pVEGFE+ significantly increased VEGF expres-
sion, compared to pVEGFE−, and that VEGF expression further 
increased with distance from the vascular pedicle. Further, in the 
distal area of the RSF pVEGFE+ resulted in similar levels of VEGF 
expression as delivery to the gastrocnemius muscle (Figure 1a, b). 
Higher VEGF expression in the distal area of the RSF, compared 
to proximal region, could be due to hypoxia-induced stabiliza-
tion of the VEGF mRNA or increased translation.32 The current 
mechanisms described for increasing VEGF mRNA stability and 
translation involve genetic regions not contained within the plas-
mid used in this study. It is possible that other currently unknown 
mechanisms could enhance VEGF levels and may be responsible 
for the increase in VEGF expression in the distal area, compared 
to the less hypoxic proximal region. Importantly, VEGF expres-
sion was transient and not detected systemically, indicating that 
the increase was localized to the delivery area, which decreases 
the possibility of the adverse side effects that can result from high 
levels and/or systemic VEGF.
Increases in eNOS resulting from pVEGFE+ and pVEGFE− 
indicate the increase in VEGF expression resulting from these 


















































Figure 3 pVeGFe+ increases healing. (a) Representative images of 
RSFs from each treatment group over the time course of the study. 
(b) pVEGFE+ accelerated skin flap healing and decreased necrosis com-
pared to all controls. Quantification of distal survival on days 7 and 14 
postoperatively; n = 7 per group, per time point. *P < 0.05, **P < 0.01 
compared to all controls. (c) Representative sections of skin excised 
2-cm from the distal end of RSF stained with hematoxylin–eosin from the 
pVEGFE+ (A,B) and pVEGFE− (C–F) treatment groups. pVEGFE+, mice 
injected with pVEGF followed by electroporation; pVEGFE−, rats injected 
with pVEGF without electroporation; RSF, random skin flaps.
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response. pVEGFE+ induces an earlier and more robust increase in 
eNOS expression compared to pVEGFE− (Figure 1c). Our results 
are consistent with reports that in vitro VEGF-induced upregula-
tion of eNOS is time and dose dependent33 and with a study by 
Huang et al.34 that demonstrated adenoviral delivery of VEGF165 to 
RSFs increased eNOS. Relative to pVEGFE−, there was a 2.2-fold 
increase in eNOS protein with pVEGFE+ in the distal area of the 
RSF at day 2 after treatment that was mediated by a 6.6-fold increase 
in VEGF protein (Figure 1b, c). Significant progress has been 
made elucidating the mechanisms underlying VEGF-mediated 
increases in eNOS, but many aspects of the complete mechanism 
remain unclear despite the well-established role of this pathway in 
wound healing and angiogenesis.34–36 In vivo34 and in vitro6,33 stud-
ies have shown that VEGF-mediated increases in eNOS protein 
levels are typically two- to fivefold over background levels at an 
optimal in vitro dosage. In the work presented here eNOS levels 
with pVEGFE+ remain similar from day 2 to day 5 after treatment, 
but increase with pVEGFE− over this time period, suggesting that 
maximal levels of eNOS has been reached in the pVEGFE+ group 
2 days after treatment. The small increase in eNOS levels, relative 
to VEGF levels, may be due to inhibition of eNOS production by 
high levels of nitric oxide.37 Also, the persistence of eNOS expres-
sion in the pVEGFE+ and pVEGFE− treatment groups at day 5 
after treatment, despite a decrease in VEGF expression, may be 
due to a VEGF-mediated increase in eNOS mRNA stability.6 eNOS 
mRNA has an normal half-life of 48 hours38 and further extending 
the half-life would allow for increases in eNOS protein to persist 
despite a decrease in VEGF levels.
The early increase in eNOS observed with pVEGFE+ could 
contribute to the increased perfusion and healing observed at 
the later time points. eNOS production of nitric oxide is impor-
tant in the early stages of skin flap healing39 and contributes to 
maintaining peripheral skin flap circulation.40 Another possible 
mechanism for the increased perfusion and healing of the RSF 
after treatment with pVEGFE+ is increased neovascularization. 
We did not observe a significant increase in vessel density (data 
not shown) on day 14 of the study in skin samples harvested 2-cm 
from the RSFs distal end. Other groups delivering exogenous 
VEGF to wound healing models have reported the same phenom-
enon of increased healing without an associated increase in vessel 
density24,41 although other studies do not discuss changes in capil-
lary density. To prevent ischemic necrosis there must be adequate 
perfusion pressure to the distal region of the skin flap.42 In this 
study, increased eNOS, and subsequently increased vasodilation, 
could be the primary mechanism of the pVEGFE+ mediated 
increase in perfusion and healing, but determination of the exact 
mechanism will require further studies.
The end goal of exogenous VEGF delivery to ischemic tissue 
is to increase the amount of nutrients supplied to the affected area 
and the rate of waste product removal by increasing vasodilation, 
vascular permeability, and angiogenesis. The strategy developed 
here to deliver VEGF to ischemic skin offers an attractive alterna-
tive to viral and recombinant protein approaches because it allows 
for control of localized expression level and duration. Further, 
direct injection of pVEGF with EP significantly increased VEGF 
expression levels, compared to direct injection of pVEGF with-
out EP, and circumvents the adverse side effects and practicality 
issues associated with viral and recombinant protein delivery 
approaches. In summary, the pVEGFE+ treatment significantly 
increased VEGF expression for 5 days after delivery and this 
short-term increase was sufficient to significantly increase eNOS, 
compared to pVEGFE− treatment 2 days after delivery. Further, 
pVEGFE+ significantly increased recovery of baseline and post-
operative perfusion as well as healing compared to all control 
treatment groups. In conclusion, electrically mediated intrad-
ermal delivery of pVEGF is a potential noninvasive therapeutic 
approach to increase perfusion and healing of ischemic wounds.
MaterIals and Methods
Cloning of the VEGF165 plasmid. The human VEGF165 plasmid was 
cloned by subcloning the hEF1–HTLV–hVEGF165 sequence from 
pBLAST49–hVEGF (Invivogen, San Diego, CA) into the backbone of 
pVAX1 (Invitrogen, Carlsbad, CA). The cytomegalovirus promoter was 
previously removed from pVAX to create a promoterless pVAX1. The 
empty vector control (pVAXE+) is the pVAX1 backbone containing the 
hEF1–HTLV promoter.
Animal model. All procedures were approved by the Animal Use and Care 
Committee of the University of South Florida College of Medicine. A total 
of 51 male Sprague–Dawley rats (275–300 g) were used in this study. Eleven 
rats were used to determine whether delivery of pVEGF to the gastrocne-
mius muscle resulted in increased VEGF expression. Twelve rats were used 
to evaluate VEGF and eNOS expression kinetics in the RSF and 28 rats 
were used for analysis of distal skin flap perfusion and survival. Prior to 
surgery and all procedures, animals were anesthetized with 2.5–3.0% iso-
flurane in oxygen. Surgeries were performed using standard aseptic tech-
nique. To create the rostral-based single pedicle RSF the left lateral flank of 
the rat was shaved and an 8 cm by 3 cm template was traced with a surgical 
marker. Full thickness incisions were made along the traced template lines. 
The flap was then elevated and sutured back to its bed using simple inter-
rupted and running stitches with 4-0 nonabsorbable sutures.
Plasmid delivery. Delivery of pVEGF to the gastrocnemius muscle. The gas-
trocnemius muscle was exposed using a 1-cm incision. Animals received 
one 50-μL injection of pVEGF (2 mg/ml) in sterile saline using a 25 gauge, 
5/8-inch length needle. The injection site was marked with one stitch using 
a 4-0 nonabsorbable suture to later identify the delivery site to be excised for 
protein extraction and assaying VEGF expression. For pVEGFE+ a four-
needle electrode array with 6-mm gap width was then placed around the 
delivery site and eight 20-ms pulses were delivered at 200 V/cm. Delivery of 
pVEGF to the RSF. Two days after surgery animals were randomized into 
one of four treatment groups (pVEGFE+, pVEGFE−, pVAXE+ or P-E−) 
and received 4–50 μL intradermal injections of plasmid DNA (2 mg/ml) 
in sterile saline (except for P-E− which did not receive any treatment). 
All injections were performed using a 25 gauge, 5/8-inch length needle 
and were centered along the midline of the skin flap at 1, 3, 5, and 7 cm 
from the RSF pedicle. Injection sites were marked with a surgical marker if 
they were to be excised later for protein extraction. Where noted proximal 
delivery sites are those at 1 and 3 cm from the pedicle and distal delivery 
sites are those at 5 and 7 cm from the pedicle. After injection of plasmid 
DNA, the four-plate electrode16 was used to deliver 8–20 ms electric pulses 
at 200 V/cm to pVAXE+ and pVEGFE+ treatment groups.
VEGF and eNOS protein expression. At the indicated time points the 
delivery sites were excised and snap frozen on dry ice. Tissue samples were 
homogenized in 1–2 ml of lysis buffer (150 mmol/l NaCl, 20 mmol/l sodium 
phosphate pH 7.4, 10% glycerol, 1% NP-40 and protease inhibitors (Roche, 
Indianapolis, IN)). Homogenates were then centrifuged at 4 °C for 10  minutes 
at 10,000 rpm. The supernatants were removed and assayed for protein expres-
sion using commercially available enzyme-linked immunosorbent assays for 
656 www.moleculartherapy.org  vol. 17 no. 4 apr. 2009 
© The American Society of Gene Therapy
Electroporation of Plasmid VEGF Promotes Healing
human VEGF165 (DY293B, R&D Systems, Minneapolis, MN) and eNOS 
(DEN00, R&D Systems) according to the manufacturer’s instructions.
Skin flap perfusion. A Laser Doppler Perfusion Imager (Moor Instruments, 
Devon, UK) was used to record perfusion at indicated time points. A low 
intensity (2 mW) laser light beam (λ = 632.8 nm) scanned the surface of 
the skin without contact at a standardized working distance of 28 cm. Scan 
modus was set at 10 ms/pixel and resolution at 256 × 256 pixels. Three 
scans were completed per time point for each animal and average perfu-
sion in arbitrary units (flux) for the distal region of the skin flap (5-cm2 
area) was determined for each time point. Baseline perfusion was assessed 
immediately before surgery. Perfusion results are reported as the percent-
age of perfusion units relative to baseline or postoperative perfusion (nor-
malized to 100%).
Skin flap survival. The percent survival of the distal 5-cm2 area of the skin 
flaps was quantitated on days 7 and 14 after surgery. Areas dark in color 
and/or covered in scabs were defined as necrotic/nonsurviving areas. Areas 
with normal skin texture and color were defined as surviving areas. The 
surviving areas were calculated using the Moor imaging software (Moor 
Instruments) and pictures were recorded using a digital camera (Nikon, 
Melville, NY).
Histology. Two weeks postoperatively animals were humanely euthanized. 
Tissue samples were excised from the center of the skin flap, 2 cm from the 
distal end, fixed in 10% neutral buffered formalin for at least 12 hours at 
room temperature, embedded in paraffin and sectioned (4 μm). If the tis-
sue was necrotic at 2 cm from the distal end, samples were excised at the 
border of the necrotic and surviving tissue. Sections were then stained with 
hematoxylin and eosin using standard protocols. Stained sections were 
analyzed using a standard light microscope (Olympus BX51; Olympus, 
Center Valley, PA) and representative fields photographed with a Spot 
Insight 2 digital camera (Diagnostic Instruments, Sterling Heights, MI).
Statistical analyses. All values are reported as the mean ± SEM unless 
otherwise noted. Analysis of VEGF expression was completed using a 
two-tailed Student’s t-test. Analysis of eNOS expression and distal perfu-
sion was completed by ANOVA with a post hoc Dunnett’s test to adjust 
for multiple comparisons to one control group (pVEGFE+). Statistical 
significance was assumed at P < 0.05. Analysis of distal RSF survival was 
completed using the Mann–Whitney–Wilcoxon test. For distal survival, 
a post hoc Bonferroni–Dunn correction was used to correct for multiple 
comparisons. All statistical analysis was completed using the Statistical 
Package for the Social Sciences (SPSS, Chicago, IL).
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